This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Relapse Analyses of a Two-Year Controlled Study of Fluphenazine Decanoate and Fluphenazine Hydrochloride

Gerard E. Hogarty, MSW; Nina R. Schooler, PhD; Richard Ulrich, MS; Frank Mussare, MSW; Peregrino Ferro, MD; Eileen Herron, RN

Arch Gen Psychiatry. 1979;36(12):1283-1294.

Abstract
• The ability of long-acting fluphenazine decanoate and oral fluphenazine hydrochloride to forestall relapse among newly discharged schizophrenic patients is examined in the context of high and low degrees of social therapy (ST). A total of 105 patients were randomly assigned to the various treatments and maintained under controlled conditions for two years or until relapse. Relapse rates for all treatments remained traditionally high. Relapse rates for long-acting fluphenazine decanoate and oral fluphenazine hydrochloride are nearly identical in the first year, indicating that drug noncompliance does not adequately explain early schizophrenic relapse. However, patients who received long-acting fluphenazine decanoate and ST have a reduced risk of relapse over time. Relapsers who received long-acting fluphenazine decanoate appeared more affectively disturbed than other relapsers, yet both groups were diagnostically and symptomatically equivalent prior to treatment. Personal discomfort and intrafamilial stress are important predictors.

Author Affiliations
From the Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine (Mr Hogarty and Mr Ulrich), the Psychopharmacology Research Branch, National Institute of Mental Health, Rockville, Md (Dr Schooler), and the Friends Medical Science Research Center, Baltimore (Mr Mussare, Dr Ferro, and Ms Herron).

Footnotes
Accepted for publication Dec 27, 1978.

Reprint requests to 3811 O'Hara St, Pittsburgh, PA 15261 (Mr Hogarty).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Historical perspective on antipsychotic long-acting injections
Johnson
Br. J. Psychiatry 2009;195:S7-S12.
ABSTRACT | FULL TEXT  

Community treatment orders and antipsychotic long-acting injections
Lambert et al.
Br. J. Psychiatry 2009;195:S57-S62.
ABSTRACT | FULL TEXT  

Psychosocial Treatments to Promote Functional Recovery in Schizophrenia
Kern et al.
Schizophr Bull 2009;35:347-361.
ABSTRACT | FULL TEXT  

Unanswered Questions in Schizophrenia Clinical Trials
Kane and Leucht
Schizophr Bull 2008;34:302-309.
FULL TEXT  

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open-label study
KEKS et al.
Br. J. Psychiatry 2007;191:131-139.
ABSTRACT | FULL TEXT  

Why indeed?: INVITED COMMENTARY ON... WHY AREN'T DEPOT ANTIPSYCHOTICS PRESCRIBED MORE OFTEN AND WHAT CAN BE DONE ABOUT IT?
Barnes
Adv. Psychiatr. Treat. 2005;11:211-213.
FULL TEXT  

Practical Application of Pharmacotherapy With Long-Acting Risperidone for Patients With Schizophrenia
Keith et al.
Psychiatr. Serv. 2004;55:997-1005.
ABSTRACT | FULL TEXT  

Three-Year Trials of Personal Therapy Among Schizophrenic Patients Living With or Independent of Family, I: Description of Study and Effects on Relapse Rates
Hogarty et al.
Focus 2004;2:146-157.
ABSTRACT | FULL TEXT  

Psychopharmacology: Underuse of Evidence-Based Treatments in Psychiatry
Fayek et al.
Psychiatr. Serv. 2003;54:1453-1456.
FULL TEXT  

Integration of Care: Integrated Treatment of Schizophrenia
Lenroot et al.
Psychiatr. Serv. 2003;54:1499-1507.
ABSTRACT | FULL TEXT  

Schizophrenia
Freedman
NEJM 2003;349:1738-1749.
FULL TEXT  

A Program for Relapse Prevention in Schizophrenia: A Controlled Study
Herz et al.
Arch Gen Psychiatry 2000;57:277-283.
ABSTRACT | FULL TEXT  

Does Participation in Psychosocial Treatment Augment the Benefit of Clozapine?
Rosenheck et al.
Arch Gen Psychiatry 1998;55:618-625.
ABSTRACT | FULL TEXT  

Relationship Enhancement Marital Therapy with a Schizophrenic Couple: A Case Study
Zahniser and Falk
The Family Journal 1993;1:136-143.
ABSTRACT  

Family Psychoeducation, Social Skills Training, and Maintenance Chemotherapy in the Aftercare Treatment of Schizophrenia: II. Two-Year Effects of a Controlled Study on Relapse and Adjustment
Hogarty et al.
Arch Gen Psychiatry 1991;48:340-347.
ABSTRACT  

Social Work Practice Research on Severe Mental Illness: Charting a Future
Hogarty
Research on Social Work Practice 1991;1:5-31.
ABSTRACT  

The Northwick Park 'Functional' Psychosis Study. Phase 2: maintenance treatment
Johnstone et al.
J Psychopharmacol 1991;5:388-395.
ABSTRACT  

Family Interventions for Schizophrenia
Tarrier and Barrowclough
Behav Modif 1990;14:408-440.
ABSTRACT  

Differential Effect of Low and Conventional Doses of Fluphenazine on Schizophrenic Outpatients With Good or Poor Information-Processing Abilities
Asarnow et al.
Arch Gen Psychiatry 1988;45:822-826.
ABSTRACT  

Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini et al.
Arch Gen Psychiatry 1988;45:79-91.
ABSTRACT  

Low- and Conventional-Dose Maintenance Therapy With Fluphenazine Decanoate: Two-Year Outcome
Marder et al.
Arch Gen Psychiatry 1987;44:518-521.
ABSTRACT  

Family Psychoeducation, Social Skills Training, and Maintenance Chemotherapy in the Aftercare Treatment of Schizophrenia: I. One-Year Effects of a Controlled Study on Relapse and Expressed Emotion
Hogarty et al.
Arch Gen Psychiatry 1986;43:633-642.
ABSTRACT  

Family Management in the Prevention of Morbidity of Schizophrenia: Clinical Outcome of a Two-Year Longitudinal Study
Falloon et al.
Arch Gen Psychiatry 1985;42:887-896.
ABSTRACT  

The Economic Costs of Schizophrenia: Implications for Public Policy
Andrews et al.
Arch Gen Psychiatry 1985;42:537-543.
ABSTRACT  

Selection of Neuroleptic Dosage
Teicher and Baldessarini
Arch Gen Psychiatry 1985;42:636-637.
ABSTRACT  

Family Factors in Schizophrenic Relapse: Replication in California of British Research on Expressed Emotion
Vaughn et al.
Arch Gen Psychiatry 1984;41:1169-1177.
ABSTRACT  

Costs and Benefits of Two Doses of Fluphenazine
Marder et al.
Arch Gen Psychiatry 1984;41:1025-1029.
ABSTRACT  

Low-Dose Neuroleptic Treatment of Outpatient Schizophrenics: I. Preliminary Results for Relapse Rates
Kane et al.
Arch Gen Psychiatry 1983;40:893-896.
ABSTRACT  

Low Serum Neuroleptic Levels Predict Relapse in Schizophrenic Patients
Brown et al.
Arch Gen Psychiatry 1982;39:998-1000.
ABSTRACT  

Antipsychotic Effects of Pimozide in Schizophrenia: Treatment Response Prediction With Acute Dextroamphetamine Response
van Kammen et al.
Arch Gen Psychiatry 1982;39:261-266.
ABSTRACT  

Long-term Pimozide Pretreatment Differentially Affects Behavioral Responses to Dextroamphetamine in Schizophrenia: Further Exploration of the Dopamine Hypothesis of Schizophrenia
van Kammen et al.
Arch Gen Psychiatry 1982;39:275-281.
ABSTRACT  

Development and Prediction of Postpsychotic Depression in Neuroleptic-Treated Schizophrenics
Mandel et al.
Arch Gen Psychiatry 1982;39:197-203.
ABSTRACT  

Fluphenazine vs Placebo in Patients With Remitted, Acute First-Episode Schizophrenia
Kane et al.
Arch Gen Psychiatry 1982;39:70-73.
ABSTRACT  

Schizoaffective Disorder and Drug-Free Improvement-Reply
Marder et al.
Arch Gen Psychiatry 1981;38:232-233.
ABSTRACT